natgillin/translations-raw huggingface dataset:
The pharmaceutical formulation of embodiment 12, which is used in combination or developed into a combined formulation with a drug selected from the group consisting of cell signal transduction inhibitors, mitosis inhibitors, alkylating agents, antimetabolites, antibiotics, growth factor inhibitors, cell cycle inhibitors, topoisomerase inhibitors, biological reaction modifiers, antihormonal agents, antiandrogen, cell differentiation/proliferation/survival inhibitors, apoptosis inhibitors, inflammation inhibitors and P-glycoprotein inhibitors. 
Farmaceutska formulacija u skladu s patentnim zahtjevom 19, koja se koristi u kombinaciji ili je razvijena u kombiniranu formulaciju s aktivnom tvari izabranom iz skupine koja se sastoji od inhibitora transdukcije staničnog signala, inhibitora mitoze, alkilirajućih sredstava, antimetabolita, antibiotika, inhibitora faktora rasta, inhibitora staničnog ciklusa, inhibitora topoizomeraze, modifikatora biološke reakcije, antihormonalnih sredstava, antiandrogena, inhibitora stanične diferencijacije / proliferacije / preživljavanja, inhibitora apoptoze, inhibitora upale i inhibitora P-glikoproteina.
A process for the purification of compound of formula I, namely Perindopril, comprising steps of: 
Postupak pročišćavanja spoja formule I, odnosno perindoprila IL.
is hydrogen, C1 to C6 alkyl, phenyl unsubstituted or substituted by C1 to C6 alkyl, COR6 acyl group (R6 being hydrogen; C1 to C6 straight chain or branched alkyl; phenyl or benzoyl respectively unsubstituted or substituted by C1 to C6 alkyl), or any group leading to hydroxyl upon biological metabolization or chemical deprotection; and salts thereof; for use in prophylaxis and/or treatment of benign prostate hypertrophy. 
Ru je vodik, C, do Cg alkil, fenil nesupstituiran ili supstituiran s C, do Cg alkilom, COR; acilnom skupinom (Rs je vodik; C; do Cg ravnolančani ili razgranati alkil; odnosno fenil ili benzoil nesupstituiran ili supstituiran s C, do Cy alkilom), ili bilo kojom skupinom koja vodi do hidroksila nakon biološke razgradnje ili kemijskog uklanjanja zaštite; i njegove soli; za uporabu u prevenciji 1/ili liječenju karcinoma prostate.
The process according to any one of claims 1 to 11, wherein the alkali metal carboxylate or quaternary ammonium carboxylate comprises a carboxylate moiety selected from the group consisting of formate, acetate, propionate, butyrate, valerate, caproate, caprylate, laurate, myristate, palmitate, stearate, oleate, linoleate, linolenate, cyclohexanecarboxylate, phenylacetate, benzoate and toluate. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 11, gdje karboksilat alkalnog metala obuhvaća karboksilatni dio odabran iz skupine koja se sastoji od formata, acetata, propionata, butirata, valerata, kaproata, laurata, miristata, palmitata, stearata, oleata, linoleata, linolenata, cikloheksankarboksilata, fenilacetata, benzoata i toluata.
The pharmaceutical composition according to claim 13, for treating and/or preventing pain. 
Farmaceutska kompozicija kao što je definirano u patentnom zahtjevu 18, za primjenu u liječenju i/ili prevenciji bolova.
In general such a process includes dehydrochlorinating 1,1,1,2,3-pentachloropropane in a reaction zone in the presence of ferric chloride to produce 1,1,2,3-tetrachloropropene and hydrogen chloride, wherein the 1,1,2,3-tetrachloropropene and the hydrogen chloride are removed from the reaction zone by distillation during the course of the dehydrochlorination reaction, for example being removed as they form, continuously or substantially continuously. 
Postupak prema zahtjevu 1, gdje se postupak dehidrokloriranja provodi uporabom reaktivne destilacijske opreme koja obuhvaća reakcijsku zonu, zonu odvajanja 1 zonu kondenzacije, gdje se 1,1,2,3-tetrakloropropen i klorovodik uklanjanju iz reakcijske zone za dehidrokloriranje putem zone odvajanja i zone kondenzacije.
A membrane separation device comprising: 
Uređaj za membransku separaciju (10) koji sadržava:
a first feed (24) for a first liner (12) such that the first liner (12) is guided onto the supporting belt (11), 
prvi dodavač (24), za prvu oblogu (12), tako da se prvu oblogu (12) navodi na nosivu vrpcu (11),
A method for treatment of type II diabetes or obesity comprising administering a composition according to claim 1 to a patient in need thereof. 
Kompozicija prema patentnom zahtjevu 12, za uporabu u liječenju dijabetesa tipa II 1li pretilosti.
In certain embodiments, the compositions of the invention are for use in methods reducing an eosinophilic inflammatory response in the treatment or prevention of asthma, or for use in methods of reducing a neutrophilic inflammatory response in the treatment or prevention of asthma. 
Pripravak prema zahtjevu 2, naznačen time da je pripravak za upotrebu u postupku liječenja ili prevencije astme, kao što je astma posredovana neutrofilima ili alergijska astma, i pri čemu je pripravak za upotrebu u postupku smanjenja neutrofilije ili eozinofilije u liječenju astme.
converting the product of step (f) to 
(g) prevođenju produkta iz koraka (f) u
A second example is the radio communication apparatus according to the first example, wherein the hopping pattern calculation section calculates the ZC sequence number by hopping the ZC sequence number used inside a CoMP set grouping the plurality of cells for performing transmission and reception in a coordinated manner, when the radio communication apparatus is set as the CoMP terminal by the CoMP mode setting section. 
Radio komunikacijski terminalni uređaj sukladno zahtjevu 1, naznačen time da je sekcija izračuna obrasca skoka (104) prilagođena za izračunavanje broja sekvence ZC koristeći prvi obrazac skoka skakajući broj ZC sekvence korišten unutar CoMP seta okupljajući pluralitet ćelija za obavljanje prijenosa i prijema na koordiniran način, kad je radio komunikacijski terminalni uređaj postavljen u CoMP način rada od strane sekcije za postavljanje načina rada CoMP.
expanding the remaining gas via a balancing valve (48) and reintroducing at least a portion of the remaining gas back into the insulation space (16), wherein in step b), only the organofluorine compound is liquefied, wherein step b1) is carried out such that the temperature increase resulting from the compression does not reach a decomposition temperature of the organofluorine compound, leaving the integrity of the organofluorine compound unaffected, and wherein after step c), the method comprises the further step of: 
širenje preostalog plina kroz ventil za balansiranje (48) i ponovno uvođenje barem dijela preostalog plina natrag u izolacijski prostor (16), pri čemu se u koraku b) ukapljuje samo organofluorinski spoj, pri čemu se korak b1) izvodi tako da porast temperature koji nastaje kompresijom ne dosegne temperaturu raspadanja organofluorinskog spoja, ne dirajući u cjelovitost organofluorinskog spoja i pri čemu se nakon koraka c) metoda sastoji od daljnjeg koraka:
In order to inject the liquid into the capsule, often needle-like elements are used which perforate the capsule from outside. 
Da bi se injektirala tekućina u čahuru često se koriste elementi koji imaju oblik igle koji probuše čahuru s vanjske strane.
In one embodiment the first fragment consists of an entire toxin A repeating domain (amino acids 1832-2710). 
(1) prvi fragment je fragment ponavljane domene toksina A i sadrži najmanje 100 aminokiselina;
The method according to claim 2, wherein the pharmaceutical composition comprises steroids, hormones, proteins, trophic factors, vitamins, non-steroid anti-inflammatory drugs, chemotherapy drugs for topical use, antibiotics, antiviral agents, local anesthetics, anticoagulants and/or fibrinolytic agents, enzymes and/or other proteases. 
Farmaceutski pripravak za upotrebu prema prethodnim patentnim zahtjevima 3 ili 4, koji sadržava steroide, hormone, proteine, tropičke faktore, vitamine, nesteroidne protuupalne lijekove, lijekove za kemoterapiju za topikalnu primjenu, antibiotike, antivirusna sredstva, lokalne anestetike, antikoagulanse i/ili fibrinolitička sredstva, enzime i/ili druge proteaze.
Within the scope of the invention is a compound for facilitating drug delivery to a target cell, consisting of the structure (retinoid)m-linker-(retinoid)n, wherein the retinoid is selected from the group consisting of vitamin A, retinoic acid, tretinoin, adapalene, 4-hydroxy(phenyl)retinamide (4-HPR), retinyl palmitate, retinal, saturated retinoic acid, and saturated, demethylated retinoic acid; and wherein m and n are independently 2, or 3;and wherein the linker is selected from the group consisting of bis-amido-PEG, tris-amido-PEG, tetra-amido-PEG, Lys-bis-amido-PEG-Lys, Lys-tris-amido-PEG-Lys, Lys-tetra-amido-PEG-Lys, Lys-PEG-Lys, PEG2000, PEG1250, PEG1000, PEG750, PEG550, and PEG-Glu. 
HR P20191463 T1 PATENTNI ZAHTJEVI Spoj za olakšavanje unošenja lijeka u ciljanu stanicu, koji sadrži strukturu (retinoid)m-veznik-(retinoid)n; pri čemu je retinoid izabran iz grupe koja sadrži vitamin A, retinsku kiselinu, tretinoin, adapalen, 4-hidroksi(fenil)retinamid (4-HPR), retinil palmitate, retinal, zasićenu retinsku kiselinu i zasićenu demetilirajuću kiselinu; pri čemu sum in neovisni 2 ili 3; 1 pri čemu je veznik izabran iz grupe koja sadrži bis-amido-PEG, tris -amido-PEG, tetra-amido-PEG, Lis-bis-amido-PEG-Lis, Lis-tris-amido-PEG-Lis, Lis-tetraamido-PEG-Lis, Lis-PEG-Lis, PEG2000, PEG1250, PEG1000, PEG750, PEG550 i PEG-Glu.
The process according to claim 7, wherein the conversion of the compound of formula (V) into the compound of formula (I) is carried out in dimethylformamide. 
Postupak za industrijsku sintezu spoja formule (1) u skladu s patentnim zahtjevom 7, naznačen time, da se pretvaranje spoja formule (V) u spoj formule (I) izvodi u dimetilformamidu.
The hybrid formulation according to claim 2, characterized in that the organic solvent is an alcohol. Use of the formulation according to claim 1 to coat substrates of different nature. Method for the preparation of the nanostructured organic-inorganic hybrid formulation composed of an organic phase based on methacrylic-silane monomers and of an inorganic phase composed of continuous silica nanodomains obtained from an alkoxy-silane precursor of claim 1, characterized by comprising the following steps: 
Hibridna formulacija prema bilo kojem od patentnih zahtjeva 1, 2 i 6, naznačena time, da smjesa fotoinicijatora uključuje bis(2,4,6-trimetilbenzoil)-fenilfosfinoksid i 2-hidroksi-2-metil-1-fenil-propan-1-on. Postupak za pripremu nanostrukturirane organsko-anorganske hibridne formulacije prema patentnom zahtjevu 1, naznačen time, da sadrži sljedeće stupnjeve:
(h-1) hydrolyzing Compound (H) to form Compound (X-2) 
(h-1) hidrolizi Spoja (H) kako bi se dobilo Spoj (X-2) O
In another embodiment the present invention provides the use of a salt of the invention in the manufacture of a medicament for the treatment of a proliferative disorder. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time što je namijenjen upotrebi u postupku liječenja proliferativnog poremećaja.
A compound of the formula or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein 
Tvar formule [image] ili stereoizomer, tautomer, ili njena farmaceutski prihvatljiva sol, pri čemu X je C1-4 alkil;
adding the remaining part of said micronized particles of a physiologically acceptable excipient to said first mixture, to obtain a second mixture, and mixing said second mixture at a speed of rotation of 16 to 32 rpm for a time of 120 to 180 minutes, to obtain said formulation, wherein the extrafine particle fraction of each active ingredient is from 20 to 35%. 
dodavanje preostalog dijela rečenih mikroniziranih čestica fiziološki prihvatljivog ekscipijensa u rečenu prvu smjesu, da se dobije druga smjesa, te miješanje rečene druge smjese pri brzini rotacije ne nižoj od 16 rpm u vremenu od najmanje 120 minuta, gdje je dugodjelujući B2-agonist odabran iz skupine koju čine formoterol, salmeterol, indakaterol, olodaterol i vilanterol;
or a pharmaceutically acceptable salt thereof. A compound selected from the group consisting of: 
Spoj ili njegova farmaceutski prihvatljiva sol, naznačen time da je odabran iz skupine koju čine:
Ar1 and Ar2 are each independently aryl groups which are substituted with 0, 1, or 2 J groups; 
Ar1 i Ar2 su aril skupine koje su supstituirane s 0, 1, ili 2 J skupinama;
A coil according to claim 1, characterized in that in the protective guard (14), the edge of the cone base with the smaller diameter is joined with the external surface of the metal tube (10) in a place situated below the male thread (11) of the tube (10). 
Navojnica prema zahtjevu 1, naznačena time, da su u zaštitnom zvonu (14) rubovi baze čunja na jednom mjestu povezani manjim promjerom s vanjskom površinom metalne cijevi (10), koje leži ispod vanjskog navoja (11) cijevi
Aqueous 20% sodium hydroxide solution (62.5 ml) was added to a solution of Mosher's ester peak 2 (2.78 g, 5.19 mmol) in methanol (185 ml) and the mixture stirred and heated to reflux for 150 minutes. 
Vodena 20%-tna otopina natrij hidroksida (62.5 ml) se doda u otopinu peak-a 2Mosher-ovog estea (2.78 g, 5.19 mmol) u metanolu (185 ml) 1 smjesa se miješa 1 zagrijava do refluksa tijekom 150 minuta.
The sterile, injectable composition of claim 22 wherein the hyaluronic acid or a salt thereof comprises hyaluronic acid crosslinked with at least one crosslinker selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,4-bis(2,3-epoxypropoxy)butane, 1,4-bisglycidyloxybutane, 1,2-bis(2,3-epoxypropoxy)ethylene and 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, an endogenous polyamine, and mixtures thereof. 
Postupak prema patentnom zahtjevu 1, naznačen time što se umrežena hijaluronska kiselina iz koraka a) prethodno dobiva iz umrežavanja ne-umrežene hijaluronske kiseline s učinkovitom količinom najmanje jednog sredstva za umrežavanje koje se bira iz skupine koja sadrži 1,4-butandiol diglicidil eter. (BDDE), 1,4-bis(2,3- epoksipropoksi)butan, = 1,4-bisglicidiloksibutan, = 1,2-bis(2,3-epoksipropoksijetilen, - 1-(2,3-epoksipropil)-2,3- epoksicikloheksan, pustrescin, spermidin, spermin, te njihovu smjesu.
A combination according to claim 1 or 2, wherein the long-acting B2 agonist is selected from the group comprising formoterol, salmeterol, GSK-597901, GSK-159797, KUL-1248, TA-2005 and QAB-149, optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Ono), CC-10004 (ex. Celgene) i MN-001 (ex. Kvorin), po izboru u obliku njihovih racemata, enantiomera, dijastereomera i mješavina navedenog te, po izboru, njihovih farmakološki kompatibilnih adicijskih soli kiselina.
Use of a calcium ferroaluminate compound comprising a CaO-Al2O3-Fe2O3 system and having a Fe2O3 content of 0.5 to 15 % by mass, a CaO • 2Al2O3 structure and a CaO/Al2O3 molar ratio in a range of from 0.15 to 0.7, as cement admixture. 
Upotreba kalcijevog feroaluminatnog spoja koji sadrži sustav CaO-Al0;-Fe,O3 i ima sadržaj FeO; od 0,5 do 15%, maseno, strukturu CaO-: 2ALO3 uz molarni omjer CaO/AbLO> u rasponu od 0,15 do 0,7, naznačena time što se spoj upotrebljava kao cementnu primjesu.
A compound according to any one of claims 1 to 4, wherein Y is O. 
Pripravak u skladu sa zahtjevom 1 ili 2, naznačen time, da Y je O.
The double stranded RNAi agent of any one of claims 1 to 5, wherein the ligand is attached to the 3' end of the sense strand. 
H Dvolančano RNAi sredstvo prema bilo kojem od zahtjeva 1 do 5, naznačeno time da je ligand vezan na 3' završetak sense lanca.
Preferably, the compound according to the invention is combined with a compound selected from the group consisting of memantine, amantadine, baclofen, R-baclofen, phenobam, acamprosate, bumetamide, carpipramine, oxytocin, vasopressin and mixtures thereof, and a pharmaceutically acceptable excipient. 
4. - Farmaceutski pripravak za njegovu upotrebu prema patentnom zahtjevu 3, naznačeno time da je kombiniran sa spojem odabranim iz skupine koju čine memantin, amantadin, baklofen, R-baklofen, fenobam, akamprosat, bumetanid, karpipramin, oksitocin, vazopresin i njihove smjese.
The wall of housing 11 adjacent window 59 includes a series of notches or other marks 61 that provide an approximate indication of the pre-load applied. 
Zid kućišta 11 uz prozor 59 sastoji se iz serije ureza ili drugih oznaka 61 koji osiguravaju informativnu indikaciju o primjenjenom predopterećenju.
The peptide as claimed in claim 1, consisting of the amino acid sequence of SEQ ID NO: 44. 
Peptid, sukladno patentnom zahtjevu 1, sadrži amino kiselinski spoj sukladno sa SEQ ID NO:11
The column was left in regeneration solution overnight to further improve the regeneration effect. 
Kolona se ostavi u regeneracijskoj otopini preko noći radi daljnjeg poboljšanja regeneracijskih učinaka.
Pharmaceutical composition for the treatment of gastrointestinal irritation disorders 
FARMACEUTSKA SMJESA ZA LIJEÄŚENJE IRITABILNOG POREMEĆAJA PROBAVNOG SUSTAVA
In other embodiments, the engineered fuel feed stock is in a densified form. 
Tehničko gorivo u skladu s patentnim zahtjevom 1, naznačeno time, da je modificirano tehničko gorivo u zgusnutom obliku.
However, similar routes for degradation of B-2,1-fructans have not been described. 
No nisu opisani slični putovi razgradnje f3-2,1- fruktana.
Oxo-1-imidazolidinyl imidazothiadiazole derivatives according to formula (I), their geometrical isomers, enantiomers, diastereomers and mixtures, or a pharmaceutically acceptable salt thereof, wherein 
Derivati okso-1-imidazolidinil imidazotiadiazola prema formuli (I), njihovi geometrijski izomeri, enantiomeri, dijastereomeri i smjese, ili njihove farmaceutski prihvatljive soli, [image] naznačeni time da
water in an amount of about 19.7% by weight of the composition; and 
vode u količini od 10,0 do 40,0 % masenog udjela pripravka,
After 4 hours, the reaction mixture was suspended in 21 of water containing 0.1 % acetic acid at pH 5. 
Nakon 4 sata, reakcijska smjesa se suspendira u 2 1 vode koja sadrži 0,1 % octene kiseline pri pH 5.
The compound or salt of claim 9 wherein said JAK is JAK2. 
Spoj ili sol prema zahtjevu 42 naznačen time da navedeni JAK je JAK2.
is an optionally substituted aliphatic, aromatic, or heteroaromatic group; is hydrogen, a nucleofugic group, or an optionally substituted aliphatic, aromatic, or heteroaromatic group; 
R! je izborno supstituirana alifatična, aromatična ili heteroaromatična grupa; R* je vodik, nukleofugalna grupa, ili izborno supstituirana alifatična, aromatična ili heteroaromatična grupa;
The compound according to claim 13, wherein the compound is 4,5- dihydroxy-2-(4-methoxyphenylthio)isophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 4,5-dihidroksi-2-(4-metoksifeniltiojizoftalonitril.
the method being characterised by initiating combustion of the gas within the expansion cylinder (104) after the expansion piston (114) reaches its top dead center position, during the expansion stroke, while the crossover valve (150) is still open. 
HR P20090436 T1 značajka je tog postupka da izgaranje plinova u ekspanzijskom cilindru (104) započinje nakon što ekspanzijski klip (114) dosegne svoju gornju mrtvu točku, tijekom ekspanzijskog takta, dok je prijelazni ventil (150) još uvijek otvoren.
In one embodiment, each —RB2, where present, is independently selected from: 
-G4 je neovisno -H ili -G*, gdje -G? je neovisno odabran od:
The method of claim 7 wherein the compound comprising a tetrahydronaphthalene moiety provided in step (i) is contacted with the chiral reagent to form in step (ii) Formula VI-R or VI-S: wherein Z is -CN, -Cl, or -CF3. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što se spoj koji sadrži tetrahidronaftalenski ostatak dobiven u koraku (i) stavlja u kontakt s kiralnim reagensom kako bi se u koraku (ii) dobilo Formulu VI-R ili VI-S:
The following non-limitative examples illustrate the present invention. 
Slijedeći primjeri su dani kao ilustracija.
The implantation of the locking nail system for arthrodesis reconstruction in calcaneus fractures, according to the invention, will now be discussed in detail. 
Sustav čavla sa zaključavanjem prema bilo kojem od zahtjeva 1 do 3, pri čemu dvije prolazne rupe (15, 16) čavla
Universal and rapid covering system according to claim 2, wherein said coupling means (10) of the cover comprises a hook applied to the most suitable point of the reinforcing fabric (6), this hook (10) can coincide with one of the hooks (9). 
Univerzalan 1 brz sustav prekrivanja prema zahtjevu 2, pri čemu navedeni spojni element (10) prekrivača sadrži kuku primijenjenu na najprikladniji dio tkanine za ojačanje (6), ova kuka (10) se može podudarati s jednom od kuka (9).
The hinge according to claim 9, wherein said rib (30) is housed within a chamber (80d) defined between the concave side of said wall (84) and said cylindrical projection (82). 
Zglobnica u skladu s patentnim zahtjevom 9, naznačena time, da je navedeno rebro (30) smješteno u komori (80d) definiranoj između konkavne strane stjenke (84) i navedenog cilindričnog izbočenja (82).
i)—A suspension of cerium(III) chloride (1.8 g) in dry tetrahydrofuran (40 ml) was stirred overnight and then cooled to −78° C. Ethylmagnesium chloride in tetrahydrofuran (25%, 3.3 ml) was added and stirring was continued for 1 h. 
- Suspenziju cerijevog(IIT) klorida (1,8 g) u suhom tetrahidrofuranu (40 ml) miješa se preko noči, te ohladi do -78 *C. Doda se etilmagnezijev klorid u tetrahidrofuranu (25 %, 3,3 ml), a s miješanjem nastavi još 1 sat.
The pharmaceutical composition of claim 9, wherein the diabetes is type 2 diabetes mellitus. The pharmaceutical composition of claim 5, wherein the metabolic syndrome is a complex disease of type 2 diabetes mellitus and obesity. 
Spoj formule (I) iz bilo kojeg od patentnih zahtjeva 5 do 8 za njegovu primjenu prema patentnom zahtjevu 5, gdje je metabolički sindrom kompleksna bolest dijabetes melitusa tipa 2 i pretilosti.
A cancer chemotherapeutic agent according to (1) or (2) above, wherein the anti-cancer agent is one or more species selected from the group consisting of a taxane anti-cancer agent, a platinum complex anti-cancer agent, a pemetrexed compound, and fluorouracil. 
10 2. Protutumorsko kemoterapijsko sredstvo u skladu s patentnim zahtjevom 1, naznačeno time, da je protutumorsko sredstvo jedna ili više vrsta odabrana iz skupine koja se sastoji od kompleksa-platine protutumorskog sredstva, 3.
wherein the sequence of (N)x comprises the sequence 5' UGAAGGGUGAAAUAUUCUC 3' (SEQ ID NO:2) and the sequence of (N')y comprises the sequence 5' GAGAAUAUUUCACCCUUCA 3' (SEQ ID NO:1); and wherein a therapeutically effective dose of said siRNA compound is to be administered intravenously to the recipient of the kidney transplant between 15 minutes and 4 hours following revascularization of the transplanted kidney, thereby preventing or reducing Delayed Graft Function in the recipient. 
(SEQID NO:1); 1 naznačen time da neku terapeutski učinkovitu dozu spomenutog spoja siRNK treba primatelju bubrežnog presatka dati intravenozno u razdoblju između 15 minuta i 4 sata nakon revaskularizacije presađenog bubrega, čime se kod primatelja sprječava ili smanjuje mogućnost odgođene funkcije presatka.
The term “bioreactor” refers to an apparatus or closed container that is used for generating biomolecules such as secreted proteins using the synthetic or chemical conversion capacity of a cell. 
Pojam,bioreaktor" se odnosi na aparat ili zatvoreni spremnik koji se rabi za proizvodnju biomolekula poput proteina koji se izlučuju na način da se rabi sintetički potencijal stanice ili stanični potencijal s kojim stanica može vršiti kemijsku pretvorbu.